Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.

Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW, VICTORIA and VICTOR Study Groups

Open source

DOI
10.1016/s0140-6736(25)01682-4
Published
2025 Sep 27
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-01682-4,
  title = {Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.},
  author = {Zannad F and O'Connor CM and Butler J and McMullan CJ and Anstrom KJ and Barash I and Bonaca MP and Borentain M and Corda S and Gates D and Ezekowitz JA and Hernandez AF and Lam CSP and Lewis EF and Lindenfeld J and Mentz RJ and Ponikowski P and Reddy YNV and Rosano GMC and Saldarriaga C and Senni M and Teixeira PP and Udelson J and Urbinati A and Vlajnic V and Voors AA and Xing A and Patel MJ and Armstrong PW and VICTORIA and VICTOR Study Groups},
  year = {2025},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(25)01682-4},
  url = {https://doi.org/10.1016/s0140-6736(25)01682-4}
}

RIS

TY  - JOUR
TI  - Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
AU  - Zannad F
AU  - O'Connor CM
AU  - Butler J
AU  - McMullan CJ
AU  - Anstrom KJ
AU  - Barash I
AU  - Bonaca MP
AU  - Borentain M
AU  - Corda S
AU  - Gates D
AU  - Ezekowitz JA
AU  - Hernandez AF
AU  - Lam CSP
AU  - Lewis EF
AU  - Lindenfeld J
AU  - Mentz RJ
AU  - Ponikowski P
AU  - Reddy YNV
AU  - Rosano GMC
AU  - Saldarriaga C
AU  - Senni M
AU  - Teixeira PP
AU  - Udelson J
AU  - Urbinati A
AU  - Vlajnic V
AU  - Voors AA
AU  - Xing A
AU  - Patel MJ
AU  - Armstrong PW
AU  - VICTORIA and VICTOR Study Groups
PY  - 2025
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(25)01682-4
UR  - https://doi.org/10.1016/s0140-6736(25)01682-4
ER  - 

APA

F, Z., CM, O., J, B., CJ, M., KJ, A., I, B., MP, B., M, B., S, C., D, G., JA, E., AF, H., CSP, L., EF, L., J, L., RJ, M., P, P., YNV, R., GMC, R., C, S., M, S., PP, T., J, U., A, U., V, V., AA, V., A, X., MJ, P., PW, A., & Groups, V. A. V. S. (2025). Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)01682-4

Source records